ImpriMed is a company engaged in the development of precision cancer treatment for canines. It provides personalized drug testing services. The Company studies patients' drug responses and helps veterinary oncologists to prescribe a final treatment. In addition, it collects gene and cell information from pets' cancer cells and organizes them in a database.
|HQ||Palo Alto, CA, US||Map|
|Employees (est.) (Jan 2021)||15||(+8%)|
ImpriMed total Funding
ImpriMed latest funding size
Time since last funding
|2 years ago|
|Draper Associates, Sazze Partners, Plug and Play, Pear Ventures, Bon Angels Venture Partners, Draper Dragon, StartX (Stanford-StartX Fund), Ironfire Ventures, Bass Investment, Blue Bear Ventures, Murex Partners, SEMA Translink Investment|
When was ImpriMed founded?
ImpriMed was founded in 2017.
Who are ImpriMed key executives?
ImpriMed's key executives are Jamin Koo, Mainak Chowdhury and David Kurtz.
How many employees does ImpriMed have?
ImpriMed has 15 employees.
Who are ImpriMed competitors?
Competitors of ImpriMed include PetIQ, Gallant Pet and Premier Veterinary Group.
Where is ImpriMed headquarters?
ImpriMed headquarters is located at 4030 Fabian Way, Palo Alto.
Where are ImpriMed offices?
ImpriMed has an office in Palo Alto.
How many offices does ImpriMed have?
ImpriMed has 2 offices.
Receive alerts for 300+ data fields across thousands of companies